MaxCyte
GBX54.88
20
+GBX4.09+8.05% Thursday 15:17
Statistics
Day High
55.5
Day Low
54.88
52W High
223
52W Low
48.84
Volume
11,902.37
Avg. Volume
-
Mkt Cap
46.31M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.072525
Actual EPS
N/A
Financials
-106.1%Profit Margin
Unprofitable6.11BRevenue
-6.49BNet Income
Analyst Ratings
$316.60Average Price Target
The highest estimate is 316.60.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MXCT.LSE. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Danaher
DHR
Mkt Cap152.13B
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Illumina
ILMN
Mkt Cap18.99B
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Editas Medicine
EDIT
Mkt Cap276.95M
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
About
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Show more...
CEO
Mr. Maher Masoud
Employees
114
Country
US
ISIN
US57777K1060
Listings
0 Comments
Share your thoughts
FAQ
What is MaxCyte stock price today?▼
The current price of MXCT.LSE is GBX54.88 GBX — it has increased by +8.05% in the past 24 hours. Watch MaxCyte stock price performance more closely on the chart.
What is MaxCyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MaxCyte stocks are traded under the ticker MXCT.LSE.
Is MaxCyte stock price growing?▼
MXCT.LSE stock has risen by +8.88% compared to the previous week, the month change is a -10.7% fall, over the last year MaxCyte has showed a -71.19% decrease.
What is MaxCyte market cap?▼
Today MaxCyte has the market capitalization of 46.31M
When is the next MaxCyte earnings date?▼
MaxCyte is going to release the next earnings report on May 13, 2026.
What were MaxCyte earnings last quarter?▼
MXCT.LSE earnings for the last quarter are -6.71 GBX per share, whereas the estimation was -5.69 GBX resulting in a -17.96% surprise. The estimated earnings for the next quarter are N/A GBX per share.
What is MaxCyte revenue for the last year?▼
MaxCyte revenue for the last year amounts to 6.11B GBX.
What is MaxCyte net income for the last year?▼
MXCT.LSE net income for the last year is -6.49B GBX.
How many employees does MaxCyte have?▼
As of April 05, 2026, the company has 114 employees.
In which sector is MaxCyte located?▼
MaxCyte operates in the Health Care sector.
When did MaxCyte complete a stock split?▼
MaxCyte has not had any recent stock splits.
Where is MaxCyte headquartered?▼
MaxCyte is headquartered in Rockville, US.